Updates are available Correction dated 2025-04-09
Click to view Correction: https://doi.org/10.1038/s41564-025-02003-w
-
Authors
Hope, William https://orcid.org/0000-0001-6187-878X
Nambiar, Sumathi
O’Brien, Seamus
Sharland, Michael
Paterson, David L.
Yin, Mo
Gilbert, Ian H.
Ferguson, Michael https://orcid.org/0000-0003-1321-8714
Peacock, Sharon J. https://orcid.org/0000-0002-1718-2782
Buchan, Iain https://orcid.org/0000-0003-3392-1650
Reza, Nada
Dubey, Vineet
Darlow, Christopher A.
Gerada, Alessandro https://orcid.org/0000-0002-6743-4271
Howard, Alex https://orcid.org/0000-0002-4195-6821
,
Alexander, Helen
Berkessel, Megan
Camera, Miguel
Dowson, Christopher
Foster, Simon
Green, Charlotte
Harrison, Freya
Hinton, Jay
Hubbard, Julia
Miles, Tim
Ranson, Neil
Schofield, Christopher
Wren, Brendan
-
Funding
Funding for this research was provided by:
Wellcome Trust (226691/Z/22/Z, 226691/Z/22/Z, 226691/Z/22/Z)
Research Councils UK (107136 36348, MR/Z505018/1)
DH | National Institute for Health Research (CL-2022-07-001)
- License Information
-
More Information
Article History
First Online: 26 March 2025
Change Date: 9 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41564-025-02003-w
Competing interests
: W.H. holds or has recently held research grants with UKRI, EU (FP7, IMI-1, IMI-2), Wellcome, F2G, Spero Therapeutics, Antabio, Pfizer, Allecra, Bugworks, Phico Therapeutics, BioVersys and the Global Antibiotic Research and Development Partnership (GARDP). He is (or has recently been) a consultant for Appili Therapeutics, F2G, Spero Therapeutics, Pfizer, GSK, Phico Therapeutics, Pulmocide and Mundipharma Research Ltd. He was a member of the Specialist Advisory Committee for GARDP (2020–2023), a member of the British Society for Antimicrobial Chemotherapy (BSAC) Breakpoint Committee (2020–2023), a member of Health Technology Appraisal (HTA) Prioritisation Committee for Hospital Care (2022–2024) and was the Specialty National Co-lead for Infection for the National Institute of Health Research (NIHR) (2020–2024). I.B. was Chief Data Scientist Advisory for AstraZeneca (2019–2023). S.N. is an employee of Johnson and Johnson; her views are her own and do not necessarily represent those of her employer. A.H. declares past personal consulting work for Pfizer outside the submitted work, and a donation from Pfizer to the University of Liverpool for a public and professional engagement project outside the submitted work. The other authors declare no competing interests.
